About
Research
Products
Investors
Careers
Agenda
fr
Press Releases
Our latest news and press releases
All
2021
2020
2019
2018
2017
2016
12
Dec
2017
18:42 E.S.T.
Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials
Read more
04
Dec
2017
16:30 E.S.T.
Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer
Read more
04
Dec
2017
16:30 E.S.T.
Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development
Read more
20
Nov
2017
16:30 E.S.T.
Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy
Read more
13
Nov
2017
16:15 E.S.T.
Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017
Read more
06
Nov
2017
19:00 E.S.T.
FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN
Read more
01
Nov
2017
16:15 E.S.T.
Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting
Read more
01
Nov
2017
16:15 E.S.T.
Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting
Read more
04
Oct
2017
16:30 E.S.T.
Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer
Read more
04
Sep
2017
22:30 E.S.T.
Cellectis to Participate in Upcoming Investor Conferences
Read more
1
2
3
Next